Lurasidone (Latuda)

Lurasidone is a second-generation (atypical) antipsychotic in the benzisothiazole chemical class, FDA-approved for schizophrenia and bipolar I depression.

Mechanism of Action

Lurasidone has a distinct, multi-receptor binding profile (Kaplan & Sadock's Comprehensive Textbook of Psychiatry):

Receptor	Action	Clinical Significance
D2 (dopamine)	High-affinity antagonist	Antipsychotic effect; occupies 60-70% of D2 receptors at 40 mg
5-HT2A (serotonin)	High-affinity antagonist	Antipsychotic + mood benefit
5-HT7	High-affinity antagonist	Proposed antidepressant & procognitive effect
5-HT1A	Partial agonist	Antidepressant & anxiolytic contribution
α2A / α2C (adrenergic)	Moderate-affinity antagonist	Minor contribution
H1 (histamine)	Negligible affinity	Explains low sedation and low weight gain
M1 (muscarinic)	Negligible affinity	Explains minimal anticholinergic effects

The 5-HT7 antagonism is a key differentiator from most other antipsychotics and is thought to contribute to lurasidone's antidepressant properties and cognitive benefits, particularly in bipolar depression.

FDA-Approved Indications

Schizophrenia - adults and adolescents (age 13-17)
Bipolar I Depression - as monotherapy in adults and pediatric patients (age 10-17)
Bipolar I Depression - as adjunctive therapy with lithium or valproate in adults

Pharmacokinetics

Bioavailability: Low (9-19%); must be taken with at least 350 calories of food to significantly improve absorption
Tmax: 1-3 hours after dose
Volume of distribution: 6,173 L (highly distributed)
Protein binding: High
Metabolism: Almost entirely via CYP3A4 (oxidative N-dealkylation, norbornane ring hydroxylation, S-oxidation); has two active and two inactive metabolites
Elimination half-life: ~18 hours (once-daily dosing)
Excretion: Primarily fecal (80%), ~9% renal

Dosing

Indication	Starting Dose	Effective Range
Schizophrenia	40 mg once daily	40-160 mg/day
Bipolar I depression (monotherapy)	20 mg once daily	20-120 mg/day
Bipolar I depression (adjunctive)	20 mg once daily	20-120 mg/day

80% of schizophrenia patients achieve optimal response at 40-80 mg/day.

Adverse Effects

Most common (schizophrenia): Somnolence, akathisia, nausea, parkinsonism/EPS

Most common (bipolar depression): Akathisia, EPS, somnolence, nausea, vomiting, diarrhea, anxiety

Metabolic profile (favorable vs. other atypicals):

Minimal weight gain
Low risk of dyslipidemia - the Maudsley Prescribing Guidelines (15th ed.) lists lurasidone among the lowest-risk antipsychotics for dyslipidemia (alongside amisulpride, aripiprazole, ziprasidone)
Low sedation (low H1 affinity)
Low anticholinergic burden (low M1 affinity)

Other adverse effects to monitor:

Orthostatic hypotension (~1.1%)
Hyperprolactinemia (as with most D2 antagonists)
Hyperglycemia / metabolic syndrome (monitor blood glucose)
Tardive dyskinesia risk (class effect)
Neuroleptic Malignant Syndrome (NMS) (rare but serious)
QTc prolongation: Generally low risk; one case report of QTc >500 ms has been documented

Black Box Warnings

Increased mortality in elderly patients with dementia-related psychosis (class warning for all antipsychotics)
Suicidal thoughts and behaviors in children, adolescents, and young adults (applies due to antidepressant indications)

Contraindications

Hypersensitivity to lurasidone or tablet components
Concomitant use with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil) - contraindicated
Concomitant use with strong CYP3A4 inducers (rifampin, St. John's wort, phenytoin, carbamazepine) - contraindicated

Drug Interactions (CYP3A4-based)

Strong CYP3A4 inhibitors: CONTRAINDICATED (massively increases lurasidone exposure)
Moderate CYP3A4 inhibitors (diltiazem, atazanavir, erythromycin, fluconazole, verapamil): Reduce lurasidone dose by half; maximum 80 mg/day (or 40 mg/day per some references)
Grapefruit / grapefruit juice: Avoid (CYP3A4 inhibition)
Strong CYP3A4 inducers: CONTRAINDICATED (may reduce efficacy to sub-therapeutic levels)

Comparison in Bipolar Depression

Per Maudsley Prescribing Guidelines (15th ed.), antipsychotics effective in acute bipolar depression include cariprazine, lumateperone, lurasidone, olanzapine (±fluoxetine), and quetiapine. A 2023 Lancet Psychiatry network meta-analysis ranked lurasidone among the more effective options for bipolar depression, with a relatively favorable tolerability profile compared to quetiapine (which causes more sedation and weight gain).

A 2026 British Journal of Psychiatry meta-analysis (PMID 40831006) confirmed lurasidone's transdiagnostic antidepressant efficacy across multiple depressive conditions in RCTs, reinforcing its antidepressant properties beyond just bipolar I. A 2026 network meta-analysis (PMID 41191868) also found lurasidone among the better-performing antipsychotics for cognitive dysfunction in schizophrenia-spectrum disorders.

Off-Label Uses

Bipolar II depression
Mixed depressive episodes
Irritability associated with autism spectrum disorder

Key Clinical Pearls

Must take with food (≥350 calories) - without food, bioavailability drops dramatically
Once-daily dosing (18h half-life) - improves adherence
No dose titration required at initiation (can start at therapeutic dose of 40 mg)
Favorable metabolic profile - a good choice when weight gain or dyslipidemia is a concern
Unique among atypicals in having strong 5-HT7 antagonism - may explain both antidepressant effects and cognitive benefits

Sources: Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Kaplan & Sadock's Synopsis of Psychiatry; Maudsley Prescribing Guidelines in Psychiatry, 15th ed.; FDA Prescribing Information (updated Jan 2025); StatPearls (Azhar & Shaban, 2025)

This is a shared conversation. Sign in to Orris to start your own chat.